DR REDDYS LABORATORIES LTD — Capital/Financing Update 2025

Jan 7, 2025

January 7, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Sale of step down wholly owned subsidiary of the Company.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as amended, we wish to inform that Dr. Reddy's Laboratories Inc, USA, the wholly owned subsidiary of the Company, has entered into an agreement for sale of all the issued and outstanding membership interests in its wholly owned subsidiary, Dr. Reddy's Laboratories Louisiana LLC (DRLL), along with manufacturing facility of DRLL in Shreveport, Louisiana, USA. Consequently, Dr. Reddy's Laboratories Louisiana LLC will cease to be a wholly owned subsidiary of Dr. Reddy's Laboratories Inc as well as step down wholly owned subsidiary of the Dr. Reddy's Laboratories Limited.

The details required under Regulation 30 of the SEBI Listing Regulations, read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above sale is given in Annexure enclosed herewith.

This is for your information and records.

Thanking you.

Yours faithfully, For Dr. Reddy's Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer, and Head-CSR KUMAR RANDHIR SINGH Digitally signed by KUMAR RANDHIR SINGH Date: 2025.01.07 18:17:38 +05'30'

Encl: as above

Annexure

Disclosure under Part A Para A(i) of Schedule III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Sl.	Particulars	Description
No
1	Theamountandpercentageoftheturnover or revenue or income and networthcontributedbysuchunitordivision or undertaking or subsidiary orassociate company of the listed entity	The details as per last audited financial statement forthe financial year ended March 31, 2024of Dr.Reddy's Laboratories Louisiana LLC(DRLL)are ashereunder:
	during the last financial year	ParticularsAmount(USD)%ofconsolidatedIncome/NetWorth of theCompany(1)0.68%(3)TurnoverUSD 38.91 million(2)
2	Date on which the agreement for sale hasbeen entered into	0.47%(3)Net worthUSD 29.49 millionJanuary 6, 2025
3	The expected date of completion ofsale/disposal	By March18, 2025
4	Considerationreceivedfromsuchsale/disposal	USD 1
5	Brief details of buyers and whether anyofthebuyersbelongtothepromoter/promotergroup/groupcompanies. If yes, details thereof	Jaguar Labs Holdings, LLC, a Delaware limitedliability company.Jaguar Labs Holdings, LLCdoes not belong to thepromoter/ promoter group/ group companies.
6	Whether the transaction would fall withinrelated party transactions? If yes, whetherthe same is done at "arm's length"	The transaction is not a related party transactionasJaguar Labs Holdings, LLCis not a related party to theCompany or any of its subsidiaries
7	Whether the sale, lease or disposal of theundertakingisoutsideSchemeofArrangement? If yes, details of the sameincluding compliance with regulation37A of LODR Regulations	No
8	Additionally, in case of a slump sale,indicativedisclosuresprovidedforamalgamation/merger, shall be disclosedby the listed entity with respect to suchslump sale	Not applicable

• (1) Turnover includes intercompany sales of USD 23 million. DRLL has only one manufacturing facility in Shreveport, Louisiana, USA. This facility is non-strategic for the Company with no future pipeline of products. No products/ANDAs are being divested as part of this transaction. Any products manufactured at the site are being tech-transferred based on commercial viability.
• (2) Net Worth is primarily comprised of Inventories and Inter-company receivables. These items are expected to be utilized/realized before the closing of the deal.
• (3) The % are computed excluding inter-company transactions.